Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

49.08 -1.15 (-2.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
What's Going On With BridgeBio Pharma Stock On Monday?
BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted. 
Via Benzinga
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
BridgeBio will receive a tiered royalty on sales that begins at the low-30% range. 
Via Investor's Business Daily
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Recap: BridgeBio Pharma Q4 Earnings
 
Via Benzinga
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Inc. (NASDAQ: BBIO) is a Stock Spotlight on 1/9
Via Investor Brand Network
2 Biotechs That Could Get Bought Out in 2024
These two biotechs have been frequent visitors to the buyout-rumor mill and for good reason. 
Via The Motley Fool
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday. 
Via Benzinga
Topics Stocks
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
From BridgeBio Pharma, Inc.
Via GlobeNewswire
3 Groundbreaking Biotech Stocks to Invest in Now
These are several biotech companies for investors seeking unique opportunities for great returns within the industry. 
Via InvestorPlace
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
These stocks to buy for growth already have a strong growth story. If they reach their potential investors could see some dynamic returns. 
Via InvestorPlace
BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
3 Russell 2000 Stocks That Are About to Get Absolutely Crushed
The Russell 2000 has only begun closing its wide gap with other indices, but investors should be weary of these three stocks to sell. 
Via InvestorPlace
BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today?
Lumos Pharma Inc (NASDAQ: LUMO) announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic (PK/PD) trial met all... 
Via Benzinga
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Rare Disease Player BridgeBio Pharma's Upside Potential Is Significant According to Citi Analyst - Here's Why
Citi initiated coverage on BridgeBio Pharma Inc (NASDAQ: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, noting an optimistic outlook on the stock. 
Via Benzinga
BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback